Autor(es):
João, Cristina ; Bergantim, Rui ; Santos, Joana ; Afonso, Celina ; Bernardo, Paulo ; Coelho, Henrique ; Costa, Carlos ; Esteves, Graça ; Freitas, José Guilherme ; Gerivaz, Rita ; Jorge, Ana ; Macedo, Ana ; Montalvão, Ana ; Neves, Manuel ; Pedrosa, Claúdia L. ; Pereira, Susana ; Roque, Adriana ; Seabra, Patrícia ; M Silva, Helena ; Silveira, Maria P. ; Tomé, Ana ; Trigo, Fernanda ; Sarmento, Ana Bela ; Lúcio, Paulo ; Geraldes, Catarina
Data: 2023
Identificador Persistente: http://hdl.handle.net/10362/155556
Origem: Repositório Institucional da UNL
Assunto(s): Multiple Myeloma/drug therapy; Portugal; Medicine(all)
Descrição
The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in recent years and the attention given to the characteristics of patients have allowed the reduction of toxicities and increased survival and quality of life of patients with multiple myeloma. These treatment recommendations from the Portuguese Multiple Myeloma Group offer guidance for first-line treatment and progression/relapse situations. These recommendations are given highlighting the data that justify each choice and referring to the respective levels of evidence that support these options. Whenever possible, the respective national regulatory framework is presented. These recommendations constitute an advance towards the best treatment of multiple myeloma in Portugal.
